Evaluation of mixture modeling with count data using NONMEM.

Abstract:

:Mixture modeling within the context of pharmacokinetic (PK)/pharmacodynamic (PD) mixed effects modeling is a useful tool to explore a population for the presence of two or more subpopulations, not explained by evaluated covariates. At present, statistical tests for the existence of mixed populations have not been developed. Therefore, a simulation study was undertaken to evaluate mixture modeling with NONMEM and explore the following questions. First, what is the probability of concluding that a mixed population exists when there truly is not a mixture (false positive significance level)? Second, what is the probability of concluding that a mixed population (two subpopulations) exists when there is truly a mixed population (power), and how well can the mixture be estimated, both in terms of the population parameters and the individual subjects classification. Seizure count data were simulated using a Poisson distribution such that each subject's count could decrease from its baseline value, as a function of dose via an Emax model. The dosing design for the simulation was based on a trial with the investigational anti-epileptic drug pregabalin. Four hundred and forty seven subjects received pregabalin as add on therapy for partial seizures, each with a baseline seizure count and up to three subsequent seizure counts. For the mixtures, the two subpopulations were simulated to differ in their Emax values and relative proportions. One subpopulation always had its Emax set to unity (Emax hi), allowing the count to approach zero with increasing dose. The other subpopulation was allowed to vary in its Emax value (Emax lo = 0.75, 0.5, 0.25, and 0) and in its relative proportion (pr) of the population (pr = 0.05, 0.10, 0.25, and 0.50) giving a total of 4.4 = 16 different mixtures explored. Three hundred data sets were simulated for each scenario and estimations performed using NONMEM. Metrics used information about the parameter estimates, their standard errors (SE), the difference between minimum objective function (MOF) values for mixture and non-mixture models (MOF (delta)), the proportion of subjects classified correctly, and the estimated conditional probabilities of a subject being simulated as having Emax lo (Emax hi) given that they were estimated as having Emax lo (Emax hi) and being estimated as having Emax lo (Emax hi) given that they were simulated as having Emax lo (Emax hi). The false positive significance level was approximately 0.04 (using all 300 runs) or 0.078 (using only those runs with a successful covariance step), when there was no mixture. When simulating mixed data and for those characterizations with successful estimation and covariance steps, the median (range) percentage of 95% confidence intervals containing the true values for the parameters defining the mixture were 94% (89-96%), 89.5% (58-96%), and 95% (92-97%) for pr, Emax lo, and Emax hi, respectively. The median value of the estimated parameters pr, Emax lo (excluding the case when Emax lo was simulated to equal 0) and Emax hi within a scenario were within +/- 28% of the true values. The median proportion of subjects classified correctly ranged from 0.59 to 0.96. In conclusion, when no mixture was present the false positive probability was less than 0.078 and when mixtures were present they were characterized with varying degrees of success, depending on the nature of the mixture. When the difference between subpopulations was greater (as Emax lo approached zero or pr approached 0.5) the mixtures became easier to characterize.

authors

Frame B,Miller R,Lalonde RL

doi

10.1023/a:1025564409649

keywords:

subject

Has Abstract

pub_date

2003-06-01 00:00:00

pages

167-83

issue

3

eissn

1567-567X

issn

1573-8744

journal_volume

30

pub_type

杂志文章
  • Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

    abstract::In this work a model for analyzing categorical data is presented; the differential odds model. Unlike the commonly used proportional odds model, this model does not assume that a covariate affects all categories equally on the log odds scale. The differential odds model was compared to the proportional odds model, by ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-008-9098-0

    authors: Kjellsson MC,Zingmark PH,Jonsson EN,Karlsson MO

    更新日期:2008-10-01 00:00:00

  • A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.

    abstract::HER2-positive breast cancer (BC) is a rapidly growing and aggressive BC subtype that predominantly affects younger women. Despite improvements in patient outcomes with anti-HER2 therapy, primary and/or acquired resistance remain a major clinical challenge. Here, we sought to use a quantitative systems pharmacological ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-020-09732-x

    authors: Franco YL,Ramakrishnan V,Vaidya TR,Mody H,Perez L,Ait-Oudhia S

    更新日期:2021-01-03 00:00:00

  • Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

    abstract::Cell-level kinetic models for therapeutically relevant processes increasingly benefit the early stages of drug development. Later stages of the drug development processes, however, rely on pharmacokinetic compartment models while cell-level dynamics are typically neglected. We here present a systematic approach to int...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9243-7

    authors: Krippendorff BF,Oyarzún DA,Huisinga W

    更新日期:2012-04-01 00:00:00

  • Review on modeling anti-antibody responses to monoclonal antibodies.

    abstract::Monoclonal antibodies (mAbs) represent a therapeutic strategy that has been increasingly used in different diseases. mAbs are highly specific for their targets leading to induce specific effector functions. Despite their therapeutic benefits, the presence of immunogenic reactions is of growing concern. The immunogenic...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-014-9367-z

    authors: Gómez-Mantilla JD,Trocóniz IF,Parra-Guillén Z,Garrido MJ

    更新日期:2014-10-01 00:00:00

  • Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.

    abstract::Target-mediated drug disposition (TMDD) is frequently reported for therapeutic monoclonal antibodies and is linked to the high affinity and high specificity of antibody molecules for their target. Understanding TMDD of a monoclonal antibody should go beyond the empirical description of its non-linear PK since valuable...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-009-9129-5

    authors: Grimm HP

    更新日期:2009-10-01 00:00:00

  • Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

    abstract::The utilisation of physiologically-based pharmacokinetic models for the analysis of population data is an approach with progressively increasing impact. However, as we move from empirical to complex mechanistic model structures, incorporation of stochastic variability in model parameters can be challenging due to the ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9418-0

    authors: Tsamandouras N,Wendling T,Rostami-Hodjegan A,Galetin A,Aarons L

    更新日期:2015-08-01 00:00:00

  • A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis.

    abstract::A hazard model of fracture was developed using individual patient data (IPD) from the NHANES (2005-2008) database and summary-level data from an aggregate dataset (AD). The AD was built by performing a comprehensive and systematic literature search of clinical studies published from 1995 to 2015, recording fracture ra...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9551-z

    authors: Eudy-Byrne RJ,Gillespie W,Riggs MM,Gastonguay MR

    更新日期:2017-12-01 00:00:00

  • Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

    abstract:AIM:Chemotherapy with indisulam causes myelosuppression. This study aimed to evaluate the influence of patient-related covariates on pharmacokinetics and pharmacodynamics, to identify patients at risk for severe myelosuppression and to develop a dosing algorithm for treatment optimization. METHODS:Pharmacokinetic and ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9111-2

    authors: Zandvliet AS,Schellens JH,Copalu W,Beijnen JH,Huitema AD

    更新日期:2009-02-01 00:00:00

  • Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.

    abstract::Mathematical modeling of drug effects maximizes the information gained from an experiment, provides further insight into the mechanisms of drug effects, and allows for simulations in order to design studies or even to derive clinical treatment strategies. We reviewed modeling of antimicrobial drug effects and show tha...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-007-9069-x

    authors: Czock D,Keller F

    更新日期:2007-12-01 00:00:00

  • Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children.

    abstract::There have been no pharmacokinetic parameters and blood-brain equilibration rate constant (k e0) of propofol obtained in a single population of children, by which propofol can be administered using a target effect-site concentration controlled infusion. Thirty-nine, American Society of Anesthesiologists Physical Statu...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9408-2

    authors: Choi BM,Lee HG,Byon HJ,Lee SH,Lee EK,Kim HS,Noh GJ

    更新日期:2015-04-01 00:00:00

  • Operating characteristics of stepwise covariate selection in pharmacometric modeling.

    abstract::Stepwise covariate modeling (SCM) is a widely used tool in pharmacometric analyses to identify covariates that explain between-subject variability (BSV) in exposure and exposure-response relationships. However, this approach has several potential weaknesses, including over-estimated covariate effect and incorrect sele...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-019-09635-6

    authors: Ahamadi M,Largajolli A,Diderichsen PM,de Greef R,Kerbusch T,Witjes H,Chawla A,Davis CB,Gheyas F

    更新日期:2019-06-01 00:00:00

  • Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.

    abstract::During the course of therapeutic drug monitoring (TDM), doses are adjusted to attain a target concentration range and a correlation between clearance (CL) and dose is introduced. In population pharmacokinetic analyses of such TDM data, CL has frequently been modeled as a function of dose. This paper demonstrates by si...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0083-6

    authors: Ahn JE,Birnbaum AK,Brundage RC

    更新日期:2005-12-01 00:00:00

  • Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.

    abstract::We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques. The aim was to summarize the population pharmacokinetic estimates of a study in appropriate statistical distributions in order to use them as Bayesian priors in consequent population pharm...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0048-9

    authors: Dokoumetzidis A,Aarons L

    更新日期:2005-08-01 00:00:00

  • A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients.

    abstract::Long term therapy with antiretroviral agents in HIV-infected patients often result in failure to suppress the virus load. Imperfect adherence to prescribed antiviral drugs is an important factor explaining the resurgence of virus. A better understanding of the factors responsible for the virological failure is importa...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9022-4

    authors: Labbé L,Verotta D

    更新日期:2006-08-01 00:00:00

  • Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.

    abstract::Changes in the reticulocyte subtype distribution (high, medium and low reticulocytes count (HR, MR, LR)) measured by flow cytometry following phlebotomy-induced stress erythropoiesis (abruptly dropping hemoglobin to 3-4 g/dl over 4-5 hr) and the pharmacodynamic (PD) relationship to the stimulated erythropoietin (EPO) ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0009-3

    authors: Al-Huniti NH,Widness JA,Schmidt RL,Veng-Pedersen P

    更新日期:2005-08-01 00:00:00

  • Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study.

    abstract::There are situations in drug development where one may wish to reduce the dimensionality and complexity of whole body physiologically based pharmacokinetic models. A technique for formal reduction of such models, based on global sensitivity analysis, is suggested. Using this approach mean and variance of tissue(s) and...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0004-8

    authors: Gueorguieva I,Nestorov IA,Rowland M

    更新日期:2006-02-01 00:00:00

  • A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

    abstract::Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) scores. Throu...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9581-1

    authors: Hu C,Yao Z,Chen Y,Randazzo B,Zhang L,Xu Z,Sharma A,Zhou H

    更新日期:2018-08-01 00:00:00

  • Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

    abstract::The purpose of this study was to evaluate whether mixed effects modeling (MEM) performs better than either noncompartmental or compartmental naïve pooled data (NPD) analysis for the interpretation of single sample per subject pharmacokinetic (PK) data. Using PK parameters determined during a toxicokinetic study in rat...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1011507100493

    authors: Hing JP,Woolfrey SG,Greenslade D,Wright PM

    更新日期:2001-04-01 00:00:00

  • Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.

    abstract::Tocilizumab is a recombinant humanized antihuman interleukin-6 receptor monoclonal antibody, which inhibits binding of IL-6 to its soluble (sIL-6R) and membrane-expressed (mIL-6R) receptors. The work investigated whether the observed decline in peripheral neutrophil and platelet counts after tocilizumab administration...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10928-011-9227-z

    authors: Gibiansky L,Frey N

    更新日期:2012-02-01 00:00:00

  • Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole.

    abstract::The aim of this study was to develop a population in vitro-in vivo pharmacokinetic model that simultaneously describe the absorption and accumulation kinetics of itraconazole (ICZ) and hydroxy-itraconazole (HICZ) in healthy subjects. The model integrated meta-models of gastrointestinal pH and gastrointestinal transit ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9555-8

    authors: Abuhelwa AY,Mudge S,Upton RN,Foster DJR

    更新日期:2018-04-01 00:00:00

  • Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients.

    abstract::Intravenous acetaminophen is a commonly used analgesic following surgery. The aims of this study were to determine the population pharmacokinetic profile of intravenous acetaminophen and its metabolites in adult surgical patients and to identify patient characteristics associated with acetaminophen metabolism in the p...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9358-0

    authors: Owens KH,Murphy PG,Medlicott NJ,Kennedy J,Zacharias M,Curran N,Sreebhavan S,Thompson-Fawcett M,Reith DM

    更新日期:2014-06-01 00:00:00

  • Clearance (née Rowland) concepts: a downdate and an update.

    abstract::A number of experimental observations in the late 1960s, early 1970s could not be explained by the pharmacokinetic theory available at that time. For example rats receiving phenobarbital as an enzyme inducing agent exhibited increased elimination of phenylbutazone in vitro in liver microsomes and in vivo in whole anim...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-010-9187-8

    authors: Benet LZ

    更新日期:2010-12-01 00:00:00

  • Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.

    abstract::The study aimed to characterize the population pharmacokinetics of amodiaquine (AQ) and its major metabolite N-desethylamodiaquine (N-DEAQ), and to assess the correlation between exposure to N-DEAQ and treatment outcome. Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included i...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9064-2

    authors: Hietala SF,Bhattarai A,Msellem M,Röshammar D,Ali AS,Strömberg J,Hombhanje FW,Kaneko A,Björkman A,Ashton M

    更新日期:2007-10-01 00:00:00

  • Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum.

    abstract::Significant arterio-venous differences in nicotine concentrations have been observed during and after cigarette smoking, nicotine nasal spray, and intravenous nicotine administration. In this paper we describe a novel mathematical method for estimating arterial blood levels from venous blood level data. The model allo...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1020957208071

    authors: Pitsiu M,Gries JM,Benowitz N,Gourlay SG,Verotta D

    更新日期:2002-08-01 00:00:00

  • Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

    abstract::The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol®) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9586-9

    authors: Zang X,Kagan L

    更新日期:2018-08-01 00:00:00

  • Fractional kinetics in drug absorption and disposition processes.

    abstract::We explore the use of fractional order differential equations for the analysis of datasets of various drug processes that present anomalous kinetics, i.e. kinetics that are non-exponential and are typically described by power-laws. A fractional differential equation corresponds to a differential equation with a deriva...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9116-x

    authors: Dokoumetzidis A,Macheras P

    更新日期:2009-04-01 00:00:00

  • Reversible jump Markov chain Monte Carlo for deconvolution.

    abstract::To solve the problem of estimating an unknown input function to a linear time invariant system we propose an adaptive non-parametric method based on reversible jump Markov chain Monte Carlo (RJMCMC). We use piecewise polynomial functions (splines) to represent the input function. The RJMCMC algorithm allows the explor...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9045-x

    authors: Kang D,Verotta D

    更新日期:2007-06-01 00:00:00

  • Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.

    abstract::The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological systems as described by mathematical (most often differential) equati...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9546-9

    authors: Gibiansky L,Gibiansky E

    更新日期:2018-02-01 00:00:00

  • Bioequivalence testing by statistical shape analysis.

    abstract::Bioequivalence testing has been traditionally centered in summary variables such as AUC, C (max) and t (max) which filter out the intrinsic information conveyed by discrete sequential concentration-time observations. Comparing entire concentration-time profiles between test and reference formulations for bioequivalenc...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9055-3

    authors: Pereira LM

    更新日期:2007-08-01 00:00:00

  • Robust population pharmacokinetic experiment design.

    abstract::The population approach to estimating mixed effects model parameters of interest in pharmacokinetic (PK) studies has been demonstrated to be an effective method in quantifying relevant population drug properties. The information available for each individual is usually sparse. As such, care should be taken to ensure t...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-2102-z

    authors: Dodds MG,Hooker AC,Vicini P

    更新日期:2005-02-01 00:00:00